How do you approach timing of repeat plasma p-tau217/Aβ42 monitoring to detect conversion in MCI due to suspected Alzheimer’s disease?

I think that this question is purely “academic” and not relevant for clinical practice. If a patient has clear evidence of MCI based on history and bedside cognitive testing results, and ptau217/Αβ42 ratio falls within the intermediate/non-diagnostic range, then the appropriate course of action, if ...